Company intelligence / Profile preview

Rivus Pharmaceuticals, Inc.

Charlottesville, Virginia, United Statesrivuspharma.com ↗

Ownership: Private
Employees: ~8
Development stage: Phase 2

Overview

Rivus has completed Phase 1 clinical studies and a Phase 2a metabolic study for its lead candidate HU6. Results from a Phase 2a study in patients with obese heart failure with preserved ejection fraction (HFpEF) were published in JAMA Cardiology. The company has completed dosing in a Phase 2 study in patients with metabolic dysfunction-associated steatohepatitis (MASH). Topline data readout from Phase 2 M-ACCEL study is planned for Q2 2025.

Therapeutic areas: GastroenterologyEndocrinologyCardiovascularMetabolic Disorders
Modalities: Small molecules
Industry: Biotech

Drug pipeline

4 assets

HU6

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Rivus Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rivus Pharmaceuticals, Inc..

Explore the full profile